Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Radhakrishnan RamchandrenRanjana H AdvaniStephen M AnsellNancy L BartlettRobert ChenJoseph M ConnorsTatyana FeldmanAndres Forero-TorresJonathan W FriedbergAjay K GopalLeo I GordonJohn KuruvillaKerry J SavageAnas YounesGerald EngleyThomas J ManleyKeenan FentonDavid J StrausPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.